Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal Stem Cells for Spinal Cord Injury
NCT05018793Phase 1Recruiting
- Sponsor
- The Foundation for Orthopaedics and Regenerative Medicine
- Start
- Dec 2024
- Primary completion
- Dec 2028
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mesenchymal stem cells in spinal cord injury (SCI), sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Primary endpoint: Safety (adverse events) at 4 years. Started Dec 2024; status: recruiting.
02
Drugs
mesenchymal stem cells
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT05018793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05018793.